2130878-25-8

The pharmacokinetic profile of TP-021 (BCL6-IN-8c, Compound 8c) is evaluated by a mouse cassette-dosing study (0.1 mg/kg iv; 1 mg/kg po). TP-021 (BCL6-IN-8c) exhibits a good pharmacokinetic profile (C_max = 233 ng/mL, T_max = 2 hours, MRT = 3.3 h, AUC = 1.27 mg h/mL, F (oral bioavailability) = 79.9%)^[1].